PL2616076T3 - Kompozycje farmaceutyczne - Google Patents

Kompozycje farmaceutyczne

Info

Publication number: PL2616076T3
Authority: PL; Poland
Prior art keywords: pharmaceutical compositions; pharmaceutical; compositions
Prior art date: 2010-09-16

Application number

PL11825920T

Other languages

English (en)

Inventor

Deepak B. Mundhra

Rennan Pan

Original Assignee

Viiv Healthcare Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-09-16

Filing date

2011-09-15

Publication date

2017-07-31

2011-09-15 Application filed by Viiv Healthcare Company filed Critical Viiv Healthcare Company

2017-07-31 Publication of PL2616076T3 publication Critical patent/PL2616076T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

PL11825920T 2010-09-16 2011-09-15 Kompozycje farmaceutyczne PL2616076T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US38354110P	2010-09-16	2010-09-16
EP11825920.9A EP2616076B1 (en)	2010-09-16	2011-09-15	Pharmaceutical compositions

Publications (1)

Publication Number	Publication Date
PL2616076T3 true PL2616076T3 (pl)	2017-07-31

Family

ID=45832235

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL11825920T PL2616076T3 (pl)	2010-09-16	2011-09-15	Kompozycje farmaceutyczne

Country Status (28)

Country	Link
US (6)	US20130171214A1 (pl)
EP (1)	EP2616076B1 (pl)
JP (1)	JP6231385B2 (pl)
KR (1)	KR101938662B1 (pl)
CN (1)	CN103547266B (pl)
AU (1)	AU2011302030B2 (pl)
BR (1)	BR112013005907B1 (pl)
CA (1)	CA2810524C (pl)
CL (1)	CL2013000715A1 (pl)
CY (1)	CY1118279T1 (pl)
DK (1)	DK2616076T3 (pl)
EA (1)	EA024924B1 (pl)
ES (1)	ES2594557T3 (pl)
HR (1)	HRP20161280T1 (pl)
HU (1)	HUE031336T2 (pl)
IL (1)	IL225028A (pl)
LT (1)	LT2616076T (pl)
ME (1)	ME02520B (pl)
MX (1)	MX346193B (pl)
PL (1)	PL2616076T3 (pl)
PT (1)	PT2616076T (pl)
RS (1)	RS55222B1 (pl)
SI (1)	SI2616076T1 (pl)
SM (1)	SMT201600350B (pl)
TW (1)	TWI577377B (pl)
UA (1)	UA108250C2 (pl)
WO (1)	WO2012037320A2 (pl)
ZA (1)	ZA201301766B (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JO3387B1 (ar)	2011-12-16	2019-03-13	Glaxosmithkline Llc	مشتقات بيتولين
EA201590862A1 (ru) *	2012-12-14	2016-05-31	ГЛАКСОСМИТКЛАЙН ЭлЭлСи	Фармацевтические композиции
WO2015108945A2 (en)	2014-01-14	2015-07-23	Board Of Regents Of The University Of Nebraska	Compositions and methods for the delivery of therapeutics
US20170165271A1 (en) *	2014-02-24	2017-06-15	The Board Of Regents Of The University Of Nebraska	Compositions and Methods for the Delivery of Therapeutics
JP2017528497A (ja) *	2014-09-26	2017-09-28	グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙ（Ｎｏ．２）Ｌｉｍｉｔｅｄ	長時間作用型医薬組成物
EP3203995A4 (en)	2014-10-09	2019-05-15	Board of Regents of the University of Nebraska	COMPOSITIONS AND METHODS OF DELIVERING THERAPY AGENTS
PH12017501005B1 (en) *	2014-12-20	2024-03-27	Troikaa Pharmaceuticals Ltd	Injectable formulations of paracetamol
US11117904B2 (en)	2016-06-23	2021-09-14	Viiv Healthcare Company	Compositions and methods for the delivery of therapeutics
WO2018175271A1 (en) *	2017-03-24	2018-09-27	Merck Sharp & Dohme Corp.	Formulation for parenteral administration
LT3943070T (lt)	2017-07-14	2024-02-12	Janssen Pharmaceutica Nv	Ilgo veikimo bedakvilino preparatai
WO2019016679A1 (en) *	2017-07-18	2019-01-24	Viiv Healthcare Company	COMBINATION THERAPY
EP3737359A4 (en)	2018-01-12	2021-11-03	Board of Regents of the University of Nebraska	ANTIVIRAL MEDICINES AND FORMULATIONS OF THEM
CA3132832A1 (en)	2018-04-09	2019-10-17	Howard E. Gendelman	Antiviral prodrugs and formulations thereof
CN113226319B (zh)	2018-10-22	2023-04-11	内布拉斯加大学董事会	抗病毒前药及其纳米制剂
WO2020112931A1 (en)	2018-11-29	2020-06-04	Board Of Regents Of The University Of Nebraska	Antiviral prodrugs and nanoformulations thereof
CN109646440B (zh) *	2019-01-11	2021-04-20	山东省农业科学院奶牛研究中心	Cabotegravir在制备抗牛传染性鼻气管炎药物中的应用
EP3938047B1 (en)	2019-03-22	2022-06-22	Gilead Sciences, Inc.	Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
AU2020402659A1 (en) *	2019-12-09	2022-06-02	Viiv Healthcare Company	Pharmaceutical compositions comprising cabotegravir
MX2022009871A (es)	2020-02-24	2022-08-19	Gilead Sciences Inc	Compuestos tetraciclicos para tratar la infeccion por el virus de la inmunodeficiencia humana (vih).
JP2023532981A (ja) *	2020-07-09	2023-08-01	ヤンセンファーマシューティカエヌ．ベー．	長時間作用型配合物
MX2023000439A (es) *	2020-07-09	2023-02-09	Janssen Pharmaceutica Nv	Formulaciones a largo plazo.
JP2023539344A (ja) *	2020-09-01	2023-09-13	ヴィーブ、ヘルスケア、カンパニー	カボテグラビルおよびレボノルゲストレルの組合せ
WO2022079739A1 (en)	2020-10-14	2022-04-21	Cipla Limited	Fixed dose compositions of cabotegravir and rilpivirine
PE20231297A1 (es)	2021-01-19	2023-08-22	Gilead Sciences Inc	Compuestos de piridotriazina sustituidos y usos de estos
TWI856796B (zh)	2022-04-06	2024-09-21	美商基利科學股份有限公司	橋聯三環胺甲醯基吡啶酮化合物及其用途
CN115844838B (zh) *	2022-12-01	2023-10-24	浙江萃泽医药科技有限公司	一种可注射的药物组合物

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR1215599A (fr) *	1958-06-27	1960-04-19	Rhone Poulenc Sa	Nouveaux dérivés de l'iminodibenzyle substitués à l'azote par une chaîne pipérazinique et leur préparation
US5352459A (en)	1992-12-16	1994-10-04	Sterling Winthrop Inc.	Use of purified surface modifiers to prevent particle aggregation during sterilization
US5484926A (en)	1993-10-07	1996-01-16	Agouron Pharmaceuticals, Inc.	HIV protease inhibitors
US6475491B1 (en)	1995-06-07	2002-11-05	Trimeris, Inc.	Treatment of HIV and other viral infections using combinatorial therapy
US5834025A (en) *	1995-09-29	1998-11-10	Nanosystems L.L.C.	Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
TW487572B (en)	1996-05-20	2002-05-21	Janssen Pharmaceutica Nv	Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
US6045829A (en)	1997-02-13	2000-04-04	Elan Pharma International Limited	Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US6066292A (en) *	1997-12-19	2000-05-23	Bayer Corporation	Sterilization process for pharmaceutical suspensions
TW518218B (en) *	1999-05-27	2003-01-21	Merck Patent Gmbh	Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
JP5160005B2 (ja) *	2000-12-28	2013-03-13	武田薬品工業株式会社	徐放性製剤
US20040077601A1 (en) *	2002-07-09	2004-04-22	Point Therapeutics, Inc.	Methods and compositions relating to isoleucine boroproline compounds
ES2273078T3 (es) *	2002-08-21	2007-05-01	Pharmacia Corporation	Suspension farmaceutica inyectable en un vial con dos camaras.
CA2523035C (en)	2003-05-22	2011-04-26	Elan Pharma International Ltd.	Sterilization of dispersions of nanoparticulate active agents with gamma radiation
EP1713443A2 (en)	2004-01-29	2006-10-25	Baxter International Inc.	Nanosuspensions of anti-retroviral agents for increased central nervous system delivery
US7985222B2 (en)	2004-04-21	2011-07-26	Medshape Solutions, Inc.	Osteosynthetic implants and methods of use and manufacture
CN101163702B (zh)	2005-04-25	2011-09-07	詹森药业有限公司	制备无菌的3-[2-[4-(6-氟-1,2-苯并异唑-3-基)-1-哌啶基]乙基]-6,7,8,9-四氢-9-羟基-2-甲基-4H-吡啶并[1,2-a]嘧啶-4-酮棕榈酸酯的方法
EP3045206B2 (en) *	2005-04-28	2023-02-15	VIIV Healthcare Company	Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
US7601355B2 (en) *	2005-06-01	2009-10-13	Northwestern University	Compositions and methods for altering immune function
CA2611592A1 (en)	2005-06-17	2006-12-21	Hospira Australia Pty Ltd	Liquid pharmaceutical formulations of docetaxel
US20070001094A1 (en)	2005-06-29	2007-01-04	Micron Technology, Inc.	Infrared filter for imagers
SG170073A1 (en) *	2006-01-20	2011-04-29	Tibotec Pharm Ltd	Long term treatment of hiv infection
US20070178051A1 (en)	2006-01-27	2007-08-02	Elan Pharma International, Ltd.	Sterilized nanoparticulate glucocorticosteroid formulations
HUE038797T2 (hu)	2006-06-23	2018-11-28	Janssen Sciences Ireland Uc	TMC278 vizes szuszpenziói
AU2008274185B2 (en) *	2007-07-12	2014-07-03	Janssen Sciences Ireland Uc	Crystalline form of (E) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile
US9439906B2 (en) *	2007-12-19	2016-09-13	Janssen Pharmaceutica Nv	Dosing regimen associated with long acting injectable paliperidone esters
TWI489994B (zh)	2008-03-17	2015-07-01	Baxter Healthcare Sa	供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
US20090311237A1 (en) *	2008-04-14	2009-12-17	Frost Gregory I	Combination therapy using a soluble hyaluronidase and a bisphosphonate
US8648119B2 (en) *	2008-05-23	2014-02-11	Otonomy, Inc.	Controlled release immunomodulator compositions and methods for the treatment of otic disorders
CN105198804B (zh) *	2008-07-25	2018-03-23	盐野义制药株式会社	用作hiv整合酶抑制剂的化合物
WO2010011815A1 (en) *	2008-07-25	2010-01-28	Smithkline Beecham Corporation	Chemical compounds
JP5572168B2 (ja)	2008-12-11	2014-08-13	ビーブ・ヘルスケア・カンパニー	カルバモイルピリドンｈｉｖインテグラーゼ阻害剤の製造方法および中間体
US8624023B2 (en)	2008-12-11	2014-01-07	Shionogi & Co., Ltd.	Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
WO2011017395A1 (en)	2009-08-04	2011-02-10	Glaxosmithkline Llc	Chemical compounds
US20110152303A1 (en)	2009-12-18	2011-06-23	Glaxosmithkline Llc	Chemical Compounds

2011
- 2011-09-14 TW TW100133064A patent/TWI577377B/zh active
- 2011-09-15 MX MX2013003037A patent/MX346193B/es active IP Right Grant
- 2011-09-15 US US13/823,316 patent/US20130171214A1/en not_active Abandoned
- 2011-09-15 PL PL11825920T patent/PL2616076T3/pl unknown
- 2011-09-15 DK DK11825920.9T patent/DK2616076T3/en active
- 2011-09-15 WO PCT/US2011/051713 patent/WO2012037320A2/en active Application Filing
- 2011-09-15 ME MEP-2016-192A patent/ME02520B/me unknown
- 2011-09-15 EP EP11825920.9A patent/EP2616076B1/en active Active
- 2011-09-15 JP JP2013529316A patent/JP6231385B2/ja active Active
- 2011-09-15 SI SI201130966A patent/SI2616076T1/sl unknown
- 2011-09-15 CN CN201180044588.5A patent/CN103547266B/zh active Active
- 2011-09-15 CA CA2810524A patent/CA2810524C/en active Active
- 2011-09-15 AU AU2011302030A patent/AU2011302030B2/en active Active
- 2011-09-15 EA EA201390233A patent/EA024924B1/ru unknown
- 2011-09-15 UA UAA201303057A patent/UA108250C2/ru unknown
- 2011-09-15 BR BR112013005907-9A patent/BR112013005907B1/pt active IP Right Grant
- 2011-09-15 RS RS20160826A patent/RS55222B1/sr unknown
- 2011-09-15 PT PT118259209T patent/PT2616076T/pt unknown
- 2011-09-15 LT LTEP11825920.9T patent/LT2616076T/lt unknown
- 2011-09-15 KR KR1020137009569A patent/KR101938662B1/ko active Active
- 2011-09-15 ES ES11825920.9T patent/ES2594557T3/es active Active
- 2011-09-15 HU HUE11825920A patent/HUE031336T2/hu unknown
2013
- 2013-03-03 IL IL225028A patent/IL225028A/en active IP Right Grant
- 2013-03-07 ZA ZA2013/01766A patent/ZA201301766B/en unknown
- 2013-03-15 CL CL2013000715A patent/CL2013000715A1/es unknown
2016
- 2016-10-04 SM SM201600350T patent/SMT201600350B/it unknown
- 2016-10-04 CY CY20161100985T patent/CY1118279T1/el unknown
- 2016-10-05 HR HRP20161280TT patent/HRP20161280T1/hr unknown
- 2016-10-13 US US15/292,394 patent/US11224597B2/en active Active
2021
- 2021-12-10 US US17/547,682 patent/US20220096469A1/en not_active Abandoned
2024
- 2024-05-31 US US18/679,621 patent/US12138264B2/en active Active
- 2024-10-01 US US18/903,119 patent/US20250017923A1/en active Pending
- 2024-10-01 US US18/903,140 patent/US20250017924A1/en active Pending

Also Published As

Publication number	Publication date
WO2012037320A3 (en)	2014-03-27
HRP20161280T1 (hr)	2016-11-18
KR20130116254A (ko)	2013-10-23
US20250017924A1 (en)	2025-01-16
EA201390233A1 (ru)	2014-03-31
TW201223529A (en)	2012-06-16
SMT201600350B (it)	2016-11-10
RS55222B1 (sr)	2017-02-28
CY1118279T1 (el)	2017-06-28
CA2810524A1 (en)	2012-03-22
SI2616076T1 (sl)	2016-11-30
ME02520B (me)	2017-02-20
CA2810524C (en)	2018-06-26
MX346193B (es)	2017-03-10
JP2014500849A (ja)	2014-01-16
KR101938662B1 (ko)	2019-01-15
EP2616076A4 (en)	2015-01-21
EA024924B1 (ru)	2016-11-30
AU2011302030B2 (en)	2015-01-22
CN103547266B (zh)	2016-04-06
LT2616076T (lt)	2016-10-10
IL225028A (en)	2017-04-30
US20220096469A1 (en)	2022-03-31
DK2616076T3 (en)	2016-10-24
BR112013005907A2 (pt)	2016-06-07
AU2011302030A1 (en)	2013-04-04
CL2013000715A1 (es)	2013-07-05
MX2013003037A (es)	2013-09-02
US20240307387A1 (en)	2024-09-19
US20250017923A1 (en)	2025-01-16
JP6231385B2 (ja)	2017-11-15
US20170027933A1 (en)	2017-02-02
PT2616076T (pt)	2016-09-30
EP2616076B1 (en)	2016-07-13
HUE031336T2 (hu)	2017-07-28
ZA201301766B (en)	2016-11-30
US12138264B2 (en)	2024-11-12
ES2594557T3 (es)	2016-12-21
CN103547266A (zh)	2014-01-29
UA108250C2 (uk)	2015-04-10
BR112013005907B1 (pt)	2021-04-27
TWI577377B (zh)	2017-04-11
WO2012037320A2 (en)	2012-03-22
EP2616076A2 (en)	2013-07-24
US20130171214A1 (en)	2013-07-04
US11224597B2 (en)	2022-01-18

Publication	Publication Date	Title
HK1246170A1 (zh)	2018-09-07	藥物組合物
ZA201300458B (en)	2013-09-25	C-met-modulator pharmaceutical compositions
IL223535A (en)	2017-02-28	Solid medicinal compositions
ZA201301766B (en)	2016-11-30	Pharmaceutical compositions
RS55566B1 (sr)	2017-05-31	Farmaceutska kompozicija
IL225457A0 (en)	2013-06-27	Pharmaceutical composition
ZA201300718B (en)	2013-08-28	Pharmaceutical compositions
ZA201207670B (en)	2013-05-29	Pharmaceutical compositions
PT2579858E (pt)	2014-07-18	Composição farmacêutica que contém ivabradina
ZA201301920B (en)	2013-10-30	Pharmaceutical composition
GB201010453D0 (en)	2010-08-04	Pharmaceutical composition
ZA201303223B (en)	2014-01-29	Pharmaceutical compositions
ZA201303177B (en)	2018-12-19	Pharmaceutical compositions
IL226554A (en)	2017-12-31	Medicinal preparations containing alisporiovir
IL221501A (en)	2016-11-30	Medicinal product containing miramistine
GB201001911D0 (en)	2010-03-24	Pharmaceutical composition
EP2560678A4 (en)	2013-09-18	PHARMACEUTICAL COMPOSITIONS
ZA201303732B (en)	2018-12-19	Pharmaceutical compositions
GB201008590D0 (en)	2010-07-07	Pharmaceutical compositions
GB201005403D0 (en)	2010-05-12	Novel pharmaceutical compositions
GB201019775D0 (en)	2011-01-05	Pharmaceutical composition